Two Phase 3 failures put nail in the coffin for Lundbeck Alzheimer’s drug
February 9, 2017Research and Development, Sales and Marketing Alzheimer's, Lundbeck, idalopirdine
Danish pharma firm Lundbeck has announced the failure of two Phase 3 trials investigating its experimental Alzheimer’s treatment idalopirdine; the …
Antibiotic-resistance being spread from flies to people
February 9, 2017Research and Development Antibiotic-resistant, bacteria, colistin, mcr-1
There has been a raft of news regarding antibiotic-resistance in the last few weeks, from the very good to the …
Sanofi & Regeneron deflect Amgen’s legal marketing block on Praluent
February 9, 2017Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, praluent
Sanofi and Regeneron have successfully won in a US Court ruling calling for the suspension of the permanent injunction of …
Bayer’s cardiovascular drug races to target in trial
February 9, 2017Research and Development, Sales and Marketing Bayer, Janssen, Xarelto
Bayer has been putting its blood-thinning drug, Xarelto, through its paces in a Phase 3 trial to determine whether it …
Ex-Novartis exec joins Ipsen as President, Head of Specialty Care
February 8, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, ipsen
Harout Semerjian has joined French pharma firm Ipsen as President, Head of Specialty Care International Region & Global Franchises, the …
Ipsen names new Head of Global Medical Affairs
February 8, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, ipsen
French pharmaceutical firm Ipsen has announced its recruitment of Dr Sotirios Stergiopoulos as its Senior Vice President and Head of …
Artificial Intelligence could take over 250,000 UK roles by 2030
February 8, 2017Medical Communications, Research and Development NHS, artificial intelligence
Ahead of the government’s expected digital strategy publication tomorrow, a new report has been released looking into how AI could …
Chan Zuckerberg Biohub kick-starts hiring with 47 recruits
February 8, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CZ Biohub, Mark Zuckerberg, Zuckerberg
The Chan Zuckerberg Biohub, otherwise known as CZ Biohub, has announced its first in-take of recruits. The appointments are predominantly …
More troubles for Teva as Israeli authorities open bribery investigation
February 8, 2017Research and Development, Sales and Marketing Teva, bribery
Teva continues to struggle this week; after being hit with the bombshell that CEO Erez Vigodman, its third chief executive …
New step in fight against antibiotic-resistant bacteria
February 8, 2017Research and Development antibiotic, antibiotic resistance, antibiotic-resistance, ucla
There is an increasing number of stories circulating regarding the threat posed by antibiotic-resistant bacteria, only last week four kilometres …
Scientists identify key role of divisive Alzheimer’s protein
February 8, 2017Research and Development Alzheimer's
Researchers from the Stark Neurosciences Research Institute at Indiana University have claimed to have finally identified the purpose of an …
Alexion hits out at NICE ruling on Strensiq
February 8, 2017Research and Development, Sales and Marketing Alexion, NICE, Strensiq
NICE has again drawn the ire of a company over its recommendation of its drug, this time round it’s Alexion …
Computational modelling predicts liver toxicity effects of 15 drugs
February 7, 2017Research and Development modelling
A team from Germany’s RWTH Aachen University, in collaboration with two researchers from Wellcome Genome Campus in the UK, have …
Mylan pays $96.5 million to settle pay-for-delay case
February 7, 2017Research and Development, Sales and Marketing Cephalon, Mylan, Teva, antitrust
Mylan has agreed to pay $96.5 million in order to settle an antitrust case. The case was related to the …
New EPO regulations bad for biotech innovation, experts claim
February 7, 2017Manufacturing and Production, Sales and Marketing EPO, IFPMA, SMEs, biotech
A recently-adopted initiative by the European Patent Office (EPO) to reduce patient examination times could lead to a stagnation of …
Abbott’s Zika virus test given FDA authorisation
February 7, 2017Manufacturing and Production, Research and Development Abbott Laboratories, Zika virus
The threat of the Zika virus, though it may have disappeared from the headlines, is still very much present. Any …
Thomas Cueni named as new IFPMA Director General
February 7, 2017Manufacturing and Production IFPMA
Thomas Cueni has become the new Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and will …
Teva’s CEO merry-go-round continues as Vigodman leaves
February 7, 2017Manufacturing and Production, Medical Communications Teva, erez vigodman
Teva has maintained its habit of changing CEOs rather frequently, as Erez Vigodman has left by “mutual agreement”. He becomes …
MSD aims to get the jump on BMS treating bladder cancer
February 6, 2017Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, MSD, keytruda, opdivo
Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …
Sanofi reinforces senior staff with two new execs
February 6, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi
Sanofi has reinforced its senior staff with a double-whammy of appointments; firstly, the French firm has announced that it is …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
